Proliferation state and polo-like kinase1 dependence of tumorigenic colon cancer cells

Stem Cells

Volumn 30, Issue 9, 2012, Pages 1819-1830

  Francescangeli, Federica ^a   Patrizii, Michele ^a   Signore, Michele ^a   Federici, Giulia ^a   Di Franco, Simone ^b   Pagliuca, Alfredo ^a   Baiocchi, Marta ^a   Biffoni, Mauro ^a   Vitiani, Lucia Ricci ^a   Todaro, Matilde ^b   De Maria, Ruggero ^c   Zeuner, Ann ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b UNIVERSITY OF PALERMO   (Italy)

^c REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Cancer stem cells; Cell cycle; Cell proliferation; Colorectal cancer

Indexed keywords

ANTINEOPLASTIC AGENT; CD133 ANTIGEN; POLO LIKE KINASE 1; POLO LIKE KINASE 1 INHIBITOR; POLO LIKE KINASE INHIBITOR; UNCLASSIFIED DRUG; VOLASERTIB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER STEM CELL; CELL PROLIFERATION; COLON CARCINOGENESIS; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE;

ANIMALS; ANTIGENS, CD; CELL CYCLE; CELL CYCLE PROTEINS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; COLONIC NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLYCOPROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; MICE, INBRED NOD; MITOCHONDRIA; PEPTIDES; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PTERIDINES; RNA, SMALL INTERFERING; TRANSPLANTATION, HETEROLOGOUS;

EID: 84865341013     PISSN: 10665099     EISSN: None     Source Type: Journal    
DOI: 10.1002/stem.1163     Document Type: Article

References (32)

1. Cunningham D, Atkin W, Lenz HJ et al. Colorectal cancer. Lancet 2010;375:1030-1047.
2. Bao S, Wu Q, McLendon RE et al. Glioma stem cells promote radio-resistance by preferential activation of the DNA damage response. Nature 2006;444:756-760.
3. Eramo A, Ricci-Vitiani L, Zeuner A et al. Chemotherapy resistance of glioblastoma stem cells. Cell Death Differ 2006;13:1238-1241.
4. Diehn M, Cho RW, Lobo NA et al. Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature 2009;458:780-783.
5. Vaiopoulos AG, Kostakis ID, Koutsilieris M et al. Colorectal cancer stem cells. Stem Cells 2012;30:363-371.
6. Maugeri-Sacca M, Vigneri P, De Maria R. Cancer stem cells and chemosensitivity. Clin Cancer Res 2011;17:4942-4947.
7. Cicalese A, Bonizzi G, Pasi CE et al. The tumor suppressor p53 regulates polarity of self-renewing divisions in mammary stem cells. Cell 2009;138:1083-1095.
8. Barker N, van Es JH, Kuipers J et al. Identification of stem cells in small intestine and colon by marker gene Lgr5. Nature 2007;449:1003-1007.
9. Fenton B, Glover DM. A conserved mitotic kinase active at late anaphase-telophase in syncytial Drosophila embryos. Nature 1993;363:637-640.
10. Strebhardt K. Multifaceted polo-like kinases: Drug targets and antitargets for cancer therapy. Nat Rev Drug Discov 2010;9:643-660.
11. Stadler WM, Vaughn DJ, Sonpavde G et al. Clinical outcome of single agent volasertib (BI 6727) as second-line treatment of patients (pts) with advanced or metastatic urothelial cancer (UC). In: ASCO ASoCo, ed. Paper presented at ASCO Annual Meeting, Chicago; 2011.
12. Ricci-Vitiani L, Lombardi DG, Pilozzi E et al. Identification and expansion of human colon-cancer-initiating cells. Nature 2007;445:111-115.
13. O'Brien CA, Pollett A, Gallinger S et al. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 2007;445:106-110.
14. Huang EH, Hynes MJ, Zhang T et al. Aldehyde dehydrogenase 1 is a marker for normal and malignant human colonic stem cells (SC) and tracks SC overpopulation during colon tumorigenesis. Cancer Res 2009;69:3382-3389.
15. Lenart P, Petronczki M, Steegmaier M et al. The small-molecule inhibitor BI 2536 reveals novel insights into mitotic roles of polo-like kinase 1. Curr Biol 2007;17:304-315.
16. Steegmaier M, Hoffmann M, Baum A et al. BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo. Curr Biol 2007;17:316-322.
17. Gavet O, Pines J. Activation of cyclin B1-Cdk1 synchronizes events in the nucleus and the cytoplasm at mitosis. J Cell Biol 2010;189:247-259.
18. Macurek L, Lindqvist A, Lim D et al. Polo-like kinase-1 is activated by aurora A to promote checkpoint recovery. Nature 2008;455:119-123.
19. Seki A, Coppinger JA, Jang CY et al. Bora and the kinase Aurora a cooperatively activate the kinase Plk1 and control mitotic entry. Science 2008;320:1655-1658.
20. Cammareri P, Scopelliti A, Todaro M et al. Aurora-a is essential for the tumorigenic capacity and chemoresistance of colorectal cancer stem cells. Cancer Res 2010;70:4655-4665.
21. Lane HA, Nigg EA. Antibody microinjection reveals an essential role for human polo-like kinase 1 (Plk1) in the functional maturation of mitotic centrosomes. J Cell Biol 1996;135:1701-1713.
22. Cogswell JP, Brown CE, Bisi JE et al. Dominant-negative polo-like kinase 1 induces mitotic catastrophe independent of cdc25C function. Cell Growth Differ 2000;11:615-623.
23. Liu X, Erikson RL. Polo-like kinase (Plk)1 depletion induces apoptosis in cancer cells. Proc Natl Acad Sci USA 2003;100:5789-5794.
24. Spankuch-Schmitt B, Bereiter-Hahn J, Kaufmann M et al. Effect of RNA silencing of polo-like kinase-1 (PLK1) on apoptosis and spindle formation in human cancer cells. J Natl Cancer Inst 2002;94: 1863-1877.
25. Rudolph D, Steegmaier M, Hoffmann M et al. BI 6727, a Polo-like kinase inhibitor with improved pharmacokinetic profile and broad antitumor activity. Clin Cancer Res 2009;15:3094-3102.
26. Barker N, van de Wetering M, Clevers H. The intestinal stem cell. Genes Dev 2008;22:1856-1864.
27. Jung P, Sato T, Merlos-Suarez A et al. Isolation and in vitro expansion of human colonic stem cells. Nat Med 2011;17:1225-1227.
28. Glinsky GV, Berezovska O, Glinskii AB. Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer. J Clin Invest 2005;115:1503-1521.
29. Grinshtein N, Datti A, Fujitani M et al. Small molecule kinase inhibitor screen identifies polo-like kinase 1 as a target for neuroblastoma tumor-initiating cells. Cancer Res 2011;71:1385-1395.
30. Hu K, Law JH, Fotovati A et al. Small interfering RNA library screen identified polo-like kinase-1 (PLK1) as a potential therapeutic target for breast cancer that uniquely eliminates tumor-initiating cells. Breast Cancer Res 2012;14:R22.
31. Graham SM, Jorgensen HG, Allan E et al. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 2002;99:319-325.
32. Roeder I, Horn M, Glauche I et al. Dynamic modeling of imatinib-treated chronic myeloid leukemia: Functional insights and clinical implications. Nat Med 2006;12:1181-1184.